Congress Enacts Most Favored Nation Pricing for Biologics and Specialty Drugs Amid State Price Controls
Congress enacted Most Favored Nation pricing for biologics and specialty drugs on May 12, 2025, aligning U.S. prices with lower international rates.
Read More